Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease

International Reviews of Immunology

Volumn 18, Issue 3, 1999, Pages 185-199

  Khoury, Samia ^a   Sayegh, Mohamed H ^b   Turka, Laurence A ^c  

^a Center for Neurologic Diseases   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B7; CD28; CTLA4Ig; T cells

Indexed keywords

EID: 0033031903     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189909043024     Document Type: Article

References (67)

1. Pattison, J., Sibley, R. and Krensky, A. 1997. Mechanisms of Allograft Rejection. 1st ed. In Immunologic Renal Disease. E. Neilson and W. Couser, eds. Lippincott-Raven Publishers, Philadelphia, pp. 331-354.
2. Sayegh, M.H., Watschinger, B. and Carpenter, C.B. 1994. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 57: 1295.
3. Janeway, C.H. and Bottomly, K. 1994 Signals and signs for lymphocyte responses. Cell 76: 275-285.
4. June, C.H., Bluestone, J.A., Nadler, L.M. and Thompson, C.B. 1994. The B7 and CD28 receptor families. Immunology Today 15(7): 321-331.
5. June, C.H., Ledbetter, J.A., Linsley, P.S. and Thompson, C.B. 1990. Role of the CD28 receptor in T cell activation. Immunol Today 11: 211-216.
6. Linsley, P.S. and Ledbetter, J.A. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11: 191-221
7. Jenkins, M.K., Ashwell, J.D. and Schwartz, R.H. 1987. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 140, 3324-3330.
8. Freeman, G.J., Borriello, F., Hodes, R.J , Reiser, H., Gribben, J.G., Ng, J.W., Kim, J., Goldberg, J.M., Hathcock, K.S., Laszlo, G , Lombard, D.B , Wang, S., Gray, G.S , Nadler, L.M. and Sharpe, A.H. 1993. Murine B7-2. an alternative CTLA4 couter-recptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178: 2185-2192
9. Linsley, P.S , Brady, W., Urnes, M., Grosmaire, L.S , Damle, N.K. and Ledbetter, J.A. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7 J. Exp. Med. 174: 561-569.
10. Linsley, P., Clark, E. and Ledbetter, J. 1990. T cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Nutl. Acad. Sci. USA 87: 5031-5035.
11. Hathcock, K , Laszio, G., Pucillo, C., Linsley, P and Hodes, R. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands. Expression and function. J. Exp. Med. 180: 631-640.
12. Kuchroo, V.K., Das, D.P., Brown, J.A., Ranger, A.M., Zamvil, S.S., Sobel, R.A., Weiner, H.L., Nabavi, N. and Glimcher, L.H. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80(5): 707-718.
13. Walunas, T.L., Bakker, C.Y. and Bluestone, J.A. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183: 2541-2550.
14. Krummel, M.F. and Allison, J.P. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540.
15. Tivol, E.A., Boriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A. and Sharpe, A.H. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
16. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, C.B., Thompson, C.B., Griesser, H. and Mak, T.W. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 270: 985-988.
17. Tivol, E., Boyd, S., McKeon, S., Borriello, F., Nickerson, P., Strom, T. and Sharpe, A. 1997. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158: 5091-5094.
18. Lenschow, D., Zeng, Y., Thistlethwaite, R., Montag, A., Brady, W., Gibson, P.S., Linsley, P.S. and Bluestone, J.A 1992. Long-term survival of xenogeniec pancreatic islet grafts induced by CTLA4Ig. Science 257: 789-792.
19. Turka, L.A., Linsley, P.S., Lin, H., Brady, W., Leiden, J.M., Wei, R.Q., Gibson, X G., Zheng, X.G., Myrdal, S., Gordon, D., Bailey, T., Bolling, S.F. and Thompson, C.B. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89: 11102-11105.
20. Lin, H., Bolling, S.F., Linsley, P.S., Wei, R.Q., Gordon, D., Thompson, C.B. and Turka, L.A. 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178: 1801-1806.
21. Sayegh, M.H. and Turka, L.A. 1995. T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. 6: 1143-1150
22. Hancock, W.W , Sayegh, M.H., Zheng, X.-G , Peach, R., Linsley, P.S. and Turka, L A 1996. Costimulatory function and expression of CD40-ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93: 13967-13972.
23. Perez, V., Parijs, L.V., Biuckians, A., Zheng, X., Strom, T. and Abbas, A. 1997. Induction of peripheral T cell tolerance in vivo required CTLA-4 engagement. Immunity 6: 411-417.
24. Pearson, T.C., Alexander, D.Z., Hendrix, R., Elwood, E.T., Linsley, P.S., Winn, K.J and Larsen, C.P. 1996. CTLA4Ig plus bone marrow induces long-term allograft survival and donor-specific unresponsiveness in the murine model. Transplantation 61: 997-1004.
25. Sayegh, M., Zheng, X-G., Magee, C., Hancock, W and Turka, L. 1997. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts. Transplantation 64. 1646-1650.
26. Russell, M.E., Hancock, W.W., Akalin, E., Wallace, A.F , Glysing-Jensen, T., Willett, T. and Sayegh, M.H. 1996. Chronic cardiac rejection in the Lewis to F344 rat model: Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97: 833-838.
27. Sayegh, M.H., Akalin, E., Hancock, W.W , Russell, M.E., Carpenter, C.B. and Turka, L A. 1995. CD28-B7 blockade after alloantigenic challange in vivo inhibits Th1 cytokines but spares Th2 J. Exp. Med. 181: 1869-1874.
28. Austyn, J.M., Hankins, D.F., Larsen, C.P., Morris, P.J., Rao, A.S. and Roake, J.A. 1994. Isolation and characterization of dendritic cells from mouse heart and kidney. J. Immunol. 152: 2401-2410.
29. Lenschow, D.J., Zeng, Y., Hathcock, K.S., Zuckerman, L.A., Freeman, G., Thistlethwaite, J.R., Gray, G.S., Hodes, R J. and Bluestone, J.A. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60: 1171-1178.
30. Zheng, X., Sayegh, M., Zheng, X.-G., Linsley, P., Peach, R., Borriello, F., Strom, A., Sharpe, A. and Turka, L. 1997. The role of donor and recipient B7-1 (CD80) in allograft rejection. J. Immunol. 159: 1169-1173.
31. Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D and Noelle, R.J. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunology Today 15: 406-411.
32. Parker, D.C., Greiner, D.L., Phillps, N.E., Appel, M.C., Steele, A.W., Durie, R.J., Noelle, R.J., Mordes, J.P. and Rossini, A.A. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92. 9560-9564.
33. Larsen, C.P., Alexander, D.Z., Hollenbaugh, D., Elwood, E.T., Ritchie, S.C., Aruffo, A., Hendrix, R. and Pearson, T.C. 1996. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD4O-gp39 pathway. Transplantation 61: 4-9.
34. Kirk, A.D., Harlan, A.M., Armstrong, N.N., Davis, T.A., Dong, Y., Gray, G.S., Hong, X., Thomas, D., Fechner, Jr., J.H. and Knechtle, S.J. 1997. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94: 8789-8794.
35. Larsen, C.P., Elwood, E.T., Alexander, D.Z , Ritchie, S.C., Hendrix, R., Tucker-Burden, C., Cho, H.R., Aruffo, A., Hollenbaugh, D , Linsley, P.S., Winn, K.J. and Pearson, T.C. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD4O and CD28 pathways. Nature 381: 434-438.
36. Grewal, I.S., Foellmer, H.G., Grewal, K.D., Xu, J., Hardardottir, F., Baron, J.L., Janeway, Jr., C.A. and Flavell, R.A. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273: 1864-1867.
37. Yang, Y. and Wilson, J M. 1996 CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273: 1862-1864.
38. Finck, B.K., Linsley, P.S and Wofsy, D. 1994. Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227.
39. Nishikawa, K., Linsley, P.S., Collins, A.B., Stamenkovic, I., McCluskey, R.T. and Andres, G. 1994. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 24: 1249-1254.
40. Cross, A H., Girard, T.J., Giacoletto, K.S., Evans, R.J., Keeling, R.M., Lin, R.F., Trotter, J.L. and Karr, R.W. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis. Using CTLA4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95: 2783-2789.
41. Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S., Sobel, R.A., Nabavi, N., Weiner, H.L. and Glimcher, L.H. 1995. B7-1 and B7-2 costimulatory molecules differentially activate the TH1/TH2 developmental pathways: Application to autoimmune disease therapy. Cell 80. 707-718.
42. Perrin, P.J., Scott, D., Quigley, L., Albert, P.S., Feder, O., Gray, G S., Abe, R., June, C.H. and Racke, M.K. 1995. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154: 1481-1490.
43. Racke, M.K., Scott, D.E., Quigley, L., Gray, G.S., Abe, R., June, C.H. and Perrin, P.J. 1995. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96: 2195-2203.
44. Khoury, S.J., Akalin, E., Chandraker, A., Turka, L.A., Linsley, P.S., Sayegh, M.H. and Hancock, W.W. 1995. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155: 4521-4524.
45. Arima, T., Rehman, A., Hickey, W.F. and Flye, M.W. 1996. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 156: 4916-4924.
46. Lenschow, D.J., Ho, S.C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K.C. and Bluestone, J.A. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181: 1145-1155.
47. Miller, S.D., Vanderlugt, C.L., Lenschow, D.J., Pope, J.G., Karandikar, N.J., Dal Canto, M.C. and Bluestone, J.A. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3: 739-745.
48. Harris, N., Peach, R., Naemura, J., Linsley, P.S., Gros, G.L. and Ronchese, F. 1997. CD80 costimulation is essential for the induction of airway eosinophilia. J. Exp. Med. 185: 177-182.
49. Gallon, L., Chandraker, A., Issazadeh, S., Peach, R., Linsley, P.S., Turka, L.A., Sayegh, M.H. and Khoury, S.J. 1997. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J. Immunol. 159: 4212-4216.
50. Azuma, M , Yssel, H., Phillips, J.H., Spits, H. and Lanier, L.L. 1993. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177: 845.
51. Prabhu Das, M.R., Zamvil, S.S., Borriello, F., Weiner, H.L., Sharpe, A.H. and Kuchroo, V.K. 1995. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur. J. Immunol. 25: 207-211.
52. Krummel, M.F. and Allison, J.P. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation (see comments), J. Exp. Med. 182(2): 459-465.
53. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C B and Bluestone, J.A. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
54. Perrin, P J., Maldonado, J.H., Davis, T.A., June, C.H. and Racke, M.K. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis J. Immunol. 157: 1333-1336.
55. Karandikar, N.J., Vanderlugt, C.L., Walunas, T.L., Miller, S D. and Bluestone, J.A. 1996. CTLA-4: a negative regulator of autoimmune disease. J Exp. Med 184: 783-788.
56. Hurwitz, A.A , Sullivan, T.J., Krummel, M F., Sobel, R.A. and Allison, J.P. 1997. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 73: 57-62.
57. Hirokawa, M., Kitabayashi, A , Kuroki, J and Miura, A.B. 1995. Signal transduction by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunology 86: 155-161.
58. Khoury, S.J., Gallon, L., Verburg, R.R., Chandraker, A., Peach, R., Linsley, P.S., Turka, L A., Hancock, W.W. and Sayegh, M.H. 1996. Ex vivo treatment of antigen presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 157: 3700-3705
59. Jenkins, M.K. and Schwartz, R.H 1987. Antigen-presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165: 302-319.
60. Miller, S.D., Wetzig, R.P. and Claman, H.N. 1979 The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 149: 758.
61. Steurer, W., Nickerson, P.W., Steele, A.W., Steiger, J., Zheng, X.X. and Strom, T.B. 1995. Ex vivo coating of islet cell allografts with murine CTLA4, Fc promotes graft tolerance. J. Immunol. 155: 1165-1174.
62. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T. and Storkus, W.J. 1996. Therapy of murine tumors with tumor peptidepulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183: 87-97.
63. Gerritse, K., Laman, J.D., Noelle, R J , Aruffo, A., Ledbetter, J.A., Boersma, W.J. and Claassen, E. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci USA 93: 2499-2504.
64. Dune, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A. and Noelle, R.J. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261: 1328-1330
65. Early, G.S., Zhao, W. and Burns, C.M. 1996. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157: 3159-3164.
66. Mohan, C., Shi, Y., Laman, J.D. and Datta, S.K. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154: 1470-1480.
67. Schaub, M., Chandraker, A., Sayegh, M.H. and Khoury, S.J 1997. Synergistic effect of CD40L/CD40 and Cd28, B7 blockade in murine EAE. Neurol (Suppl.) 48: A420-421.